Jonathan S. Zager, MD, on Results of Phase 3 FOCUS Trial Examining Percutaneous Hepatic Perfusion in Ocular Melanoma With Hepatic Metastases
Source: Cancer Network, September 2022
Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.
At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Jonathan S. Zager, MD, chief academic officer in the departments of Cutaneous Oncology and Sarcoma at Moffitt Cancer Center and chair in the department of Oncologic Sciences at the University of Southern Florida, about the phase 3 FOCUS trial (NCT02678572) in which patients with hepatic-dominant ocular melanoma were randomized 1:1 to either percutaneous hepatic perfusion (PHP) or best alternative care (BAC).
In patients receiving PHP compared with BAC, the median overall survival was 19.25 months (95% CI, 16.72-24.35) vs 14.49 months (95% CI, 11.10-19.78), the median duration of response was 14 months (95% CI, 8.31-17.74) vs not calculable (NC; 95% CI, 6.93-NC), and objective response rates were 36.3% (95% CI, 26.44%-47.01%) vs 12.5% (95% CI, 3.51%-28.99%), respectively.